Over the past decade, treatment of neovascular age-related macular degeneration has evolved from overall retinal ablation to more targeted and retinal-sparing therapy, beginning with the advent of photodynamic therapy and continuing with the development of inhibitors to vascular endothelial growth factor (VEGF). This article summarizes the key clinical trials with photodynamic and anti- VEGF therapies to provide insight into and a framework around which we can choose the optimal treatments (including dosing) for our patients
